The first healthy volunteer has been dosed in a Phase 1 study of Cellarity's novel globin-switching therapy CLY-124 for ...

As a result of being a caregiver for her cousin, columnist Sylvia Amuta says she's now more caring, compassionate, and kind ...

Considering a change to your treatment regimen? Columnist Mary Shaniqua shares tips to help patients and providers make an ...

Higher pain scores upon discharge from the emergency department may predict hospitalization in adolescents with SCD, a study ...

Most people with SCD seem to meet or exceed current level of physical activity recommendations for the general population, a ...

To mark four years of sharing his experiences through writing, columnist Dunstan Nicol-Wilson reflects on the journey with gratitude.

The treatment’s developer, Beam Therapeutics, shared data from the first 17 patients dosed in the trial in a presentation, “ Base editing for sickle cell disease: ongoing results from the BEACON study ...